Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

But because we don’t know what’s driving it, we don’t know what to go after.” The study was supported by Sanofi. Cree is a co ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00. David Risinger has given his Buy rating due to a ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi will keep a significant stake in the ... Finally, we've shared several positive phase 3 readouts, including ...

Sanofi also has a strong immunology and neuro-inflammation pipeline, which includes some potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements.